US IPO Pipeline SEC S-1 Filings — August 18, 2026

Shelf registration at $11.56 may enable selling securityholders to unload up to 75M shares; no issuer proceeds creates potential overhang without signaling management confidence

Implied Fathom acquisition value of ~$1.34/share is low relative to typical REIT multiples; Fathom board unanimously recommends, but dilution risk from bridge debt may erode value further

S-4 filing for business combination with no named counterparty adds execution uncertainty; collaboration with LegoChem Biosciences (Aug 6, 2026) hints at deal rationale but lacks detail

Emerging growth company status reduces near-term compliance costs but limits investor visibility; no revenue/expense data in filing signals pre-commercial stage

Exchange ratio of 0.2236 (0.2229 adjusted) could drop to 0.2081 if all options/restricted stock are exercised; significant dilution for existing NXH shareholders

Retained earnings deficit deepened from end of 2024 through June 2026; no revenue disclosed—cash burn likely accelerating with no near-term approval catalyst

Rule 415 'shelf' registration allows flexible timing; management may time sales to market conditions, providing some price protection

Up to 75M shares registered for resale; if float is small, even partial selling could depress $11.56 price

Maximum potential exchange ratio fall from 0.2236 to 0.2081 (6.5% drop) due to share-based compensation; bridge note adds further uncertainty

Deepening deficit and no revenue; S-4 for business combination implies necessity to find partner or risk cash depletion

S-1 filed without any financial metrics indicates early-stage; post-combination entity may lack near-term commercialization

Implied $1.34 per Fathom share vs $6.02 NXH price; wide gap suggests market doubts deal close or fair value

**NextCure/Unnamed Counterparty Lack of transparency on who NextCure is merging with—could be distressed entity or share-for-share deal

If FRNM shares trade below $11.56 post-registration, selling pressure may create entry point; watch for insider buying as vote of confidence

If Fathom stockholders approve, current NXH price ($6.02) vs implied Fathom value ($1.34) offers 4.5x arbitrage if deal closes—high risk but high reward

Collaborative agreement with LegoChem Biosciences (Aug 6) could be precursor to novel platform; S-4 filing history reveals reverse-merger possibilities with biotech upside

Fathom is a real estate technology platform; if NXH reduces float and assets, could trade up as fintech play

Freenome’s focus on multi-cancer early detection aligns with high-growth diagnostics trend; shelf filing doesn’t preclude positive clinical data

**NextCure/Cash Position If any cash remains from 2025, post-merger entity could have capital for R&D; look for balance sheet details in full S-4

Both Freenome and Neighborhood Intelligence are de-SPAC or merger entities with significant share overhangs; valuation adjustments come from seller exits, not operational performance

All three filings are resale registrations or merger proxies, not capital raises; IPO pipeline now sees secondary offerings as primary exit for existing investors

NextCure’s deepening retained deficit and lack of revenue mirrors biotech trend of cash-poor companies seeking M&A as lifeline, adding sector-wide contagion risk

Freenome uses emerging growth company status to reduce disclosure, limiting investor ability to assess fundamentals; common tactic in early-stage IPOs

Monitor $11.56 level; if breaks below, selling pressure from shelf registration could accelerate; next catalyst is first post-combination earnings (date TBD)

Watch for amendment clarifying counterparty name; key to assessing merger synergies and management quality

Monitor Fathom shareholder meeting date; any vote delay or opposition would signal deal risk

Filing expected to include pro-forma balance sheet; watch for cash position below $20M indicating urgent need for deal

Even without earnings, any press release on diagnostic trial results could overshadow share overhang

Watch for debt repayment or extension; conversion could dilute further and change exchange ratio

All S-1s and S-4s face SEC review; delays or material revisions indicate scrutiny and could alter deal timelines